Question to the Department of Health and Social Care:

To ask His Majesty's Government whether they are considering using the new screening technology, developed by OsteoSight, for estimating bone mineral density from routine X-rays that has been approved by the Food and Drug Administration in the United States to give earlier diagnosis of osteoporosis.

OsteoSight is not a registered product with the Medicines and Healthcare Products Regulatory Agency, therefore the Government is not currently considering the use of this technology. However, we will continue to explore areas where artificial intelligence can be deployed in health and care to support clinicians, transform patient experience and improve outcomes.